share_log

HC Wainwright & Co. Maintains Buy on MiNK Therapeutics, Lowers Price Target to $9

HC Wainwright & Co. Maintains Buy on MiNK Therapeutics, Lowers Price Target to $9

HC Wainwright & Co.维持对MinK Therapeutics的买入,将目标股价下调至9美元
Moomoo 24/7 ·  03/21 11:27

HC Wainwright & Co. analyst Emily Bodnar maintains MiNK Therapeutics (NASDAQ:INKT) with a Buy and lowers the price target from $10 to $9.

HC Wainwright & Co. 分析师艾米丽·博德纳尔维持MinK Therapeutics(纳斯达克股票代码:INKT)的买入并将目标股价从10美元下调至9美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发